Abstract
It is necessary to define the conditions under which immunotherapy for asthma may be reasonable considered. The disease has been divided into intrinsic and extrinsic varieties. It permits the segregation of a group of patients for whom no possible offending allergen can be identified and in whom, therefore, there is no basis for immunotherapy. Immunotherapy causes a number of immunologic changes [immunoglobulins G and E] that are associated with amelioration of symptoms. The relative merits of immunotherapy for human asthma are discussed. Animal studies are cited.